Cancer is a multifactorial disease in which both genetic and environmental factors play a role. The early detection of a tumour and its correct classification allows access to a targeted therapy that is specific for each tumour.
Around 5-10% of cancer cases are hereditary. Identification of the molecular cause of such cancers using genetic diagnosis allows the family risks to be estimated and the preventive measures or treatments available to be established.
IMEGEN has developed a series of specific tools based on the analysis of a large number of genes associated with the most common types of cancer:
Detection of biomarkers associated with different types of tumour that allow access to specific treatments for each tumour. One example of this is the alterations to the genes KRAS and BRAF found in the therapeutic management of colorectal cancer. The therapy, dose and treatment efficacy of these types of cancer are governed by the presence or absence of such genetic markers.
Please fill out the form below to request any information about our products and services, or call us at +34 963 212 340.